Jeffrey Fischer

Echo Therapeutics: A Gross Disregard To Shareholder Value

Secondary equity offerings (& unfortunate shareholder dilution) are extremely common for development-stage medical companies, but the recent secondary offering by ECHO Therapeutics (NASDAQ:ECTE) demonstrates almost unparalleled disregard for shareholder value. Remaining shareholders should make note of the company's gross negligence exhibited in the management of its finances. Even if you believe strongly in Echo's Symphony glucose monitoring system, you may want to exit your position solely based on the lack of financial leadership that has led to a 50% decline in shareholder value from June 6 to June 14.

It has been a horrific comedy of errors at Echo, and it's difficult to pinpoint the most glaring blunder - that the company had already just tapped equity markets...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details